LUCID DIAGNOSTICS INC.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lucid Diagnostics stock, expecting it to rise significantly in value.
Financial Health
Lucid Diagnostics is generating modest revenue and cash flow, indicating stable but limited financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LUCD
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap dynamics
Smaller market capitalisation can mean faster growth potential but also greater share price swings and lower liquidity; suitable only for risk‑tolerant investors.
Technology & approvals
Progress depends on product development and regulatory milestones, which can materially affect outlook—both upside and downside are possible.
Market adoption factors
Commercial adoption, reimbursement and partnerships influence long‑term prospects; performance can vary across regions and payor systems.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Thermo Fisher Scientific, Inc.
Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.
Intuitive Surgical, Inc.
A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties
